ClinicalTrials.gg
RecruitingNCT07283380ORAVAP-RCTUpdated Nov 9, 2026

Effect of Two Oral Care Methods on Oral Flora and VAP in Mechanically Ventilated Patients

An interventional study of Pediatric toothbrush and Sponge stick in Ventilator Associated Pneumonia ( VAP), sponsored by Marmara University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Marmara University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Nov 9, 2026Now RecruitingStudy documents posted+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies in Pneumonia, Ventilator-Associated with a site in Turkey — 4 open to participants now, 4 under way, none of them phase 3. Pneumonia, Ventilator-Associated · Turkey.

Planned enrollment
10th of 13
72 · median 138
Started
2025
with 2 others
No phase
7 of 20
3 open now
Registered
19th of 20
by date

Among the 20 studies in Pneumonia, Ventilator-Associated with a site in Turkey, this one is the 10th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2025, is one of 7 with no phase, and was the 19th registered.

Pneumonia, Ventilator-Associated

420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.

Browse Pneumonia, Ventilator-Associated studies →

Open to participants now

4 of the 20 studies in Pneumonia, Ventilator-Associated with a site in Turkey are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Pneumonia, Ventilator-Associated with a site in Turkey, or all of them as a file.
02

Study summary

This single-centre, parallel-group, randomised controlled trial aims to compare the effects of two oral care methods on oral microbial colonisation and ventilator-associated pneumonia (VAP) in mechanically ventilated adult intensive care unit patients. The study is being conducted in the Anaesthesia and General Intensive Care Unit of a hospital in Türkiye, with data collection planned from October 2025 to March 2027.

A total of 46 patients are planned to be enrolled and randomly allocated in a 1:1 ratio to receive oral care using either a paediatric toothbrush or a foam swab. Oral care is provided for five consecutive days. In both groups, 0.12% chlorhexidine is used twice daily, while normal saline is used for additional oral care. Oral care frequency is determined by daily assessments using the Oral Care Assessment Scale for Intensive Care Patients (OCAS-ICP).

Oropharyngeal swab samples are collected on days 1 and 6 to assess changes in microbial colonisation through the presence or absence of growth of bacterial pathogens and Candida species. VAP development is evaluated through clinical assessment supported by the Clinical Pulmonary Infection Score (CPIS). Assessors evaluating microbiological outcomes and VAP development are blinded to group allocation.

The primary outcomes are changes in oral microbial colonisation and the development of VAP. The secondary outcome is oral care frequency. The study is expected to provide evidence on the comparative effects of the two oral care methods in mechanically ventilated intensive care patients.

Read the detailed description

This study is a single-centre, parallel-group, randomised controlled trial designed to compare the effects of two oral care methods on oral microbial colonisation and the development of ventilator-associated pneumonia (VAP) in mechanically ventilated adult intensive care unit (ICU) patients. The two methods are oral care performed using a paediatric toothbrush and oral care performed using a foam swab.

The study is being conducted in the Anaesthesia and General Intensive Care Unit of a hospital in Türkiye, with data collection planned from October 2025 to March 2027. A total of 46 eligible patients are planned to be enrolled and randomly allocated in a 1:1 ratio to the paediatric toothbrush group or the foam swab group.

Oral care is provided for five consecutive days. In both groups, 0.12% chlorhexidine is used twice daily, while normal saline is used for additional oral care. The frequency of oral care is determined by daily assessments using the Oral Care Assessment Scale for Intensive Care Patients (OCAS-ICP), developed by the researchers. The scale assesses oral and clinical conditions to guide individualised oral care frequency.

Oropharyngeal swab samples are collected on days 1 and 6 to evaluate changes in microbial colonisation. Microbiological assessments include the presence or absence of growth of bacterial pathogens, including Staphylococcus spp., Pseudomonas spp. and Acinetobacter spp., as well as Candida species. Findings are documented using the Microbiology Patient Follow-up Form.

The development of VAP is evaluated through clinical assessment supported by the Clinical Pulmonary Infection Score (CPIS). The CPIS incorporates body temperature, leukocyte count, tracheal secretions, oxygenation, chest radiographic findings and microbiological results. CPIS assessments are performed at baseline and on day 6, and findings are recorded using the Clinical Pulmonary Infection Score Patient Follow-up Form.

Assessors evaluating microbiological outcomes and VAP development are blinded to group allocation. The primary outcomes are changes in oral microbial colonisation and the development of VAP. The secondary outcome is oral care frequency determined using the OCAS-ICP.

The study is expected to provide evidence on the comparative effects of oral care using a paediatric toothbrush versus a foam swab on oral microbial colonisation and VAP development in mechanically ventilated ICU patients.

03

Conditions studied

  • Ventilator Associated Pneumonia ( VAP)

Keywords

  • Oral Care
  • Oral Bacterial Colonization
  • Mechanically Ventilated Patients
04

Who can participate

The criteria were revised on the registry on Nov 9, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have been on invasive mechanical ventilation for 24 hours or less
  • Patients who provide through their legal representative or themselves if capable.
  • Patients with no prior oral surgery, no head or neck trauma, and no to oral care.
  • Patients aged 18 years or older.

Exclusion criteria

Exclusion Criteria:

  • Patients under 18 years of age.
  • Patients who have been on invasive mechanical ventilation for more than 24 hours before enrollment.
  • Patients with oral surgical procedures or trauma to the head or neck.
  • Patients with to oral care, such as severe oral bleeding, mucositis, or active oral infections.
  • Patients or legal representatives who do not provide .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Pediatric toothbrush group

    Patients will receive oral care with a pediatric toothbrush for 5 days. Oral swabs and CPIS scores will be monitored.

    Device: Pediatric toothbrush

  • Active comparator
    Sponge stick group

    Patients will receive oral care with a sponge stick for 5 days. Oral swabs and CPIS scores will be monitored.

    Device: Sponge stick

Interventions

  • DevicePediatric toothbrush

    Oral care will be using a pediatric toothbrush for 5 days; oral swabs and CPIS scores will be monitored.

  • DeviceSponge stick

    Oral care will be using a sponge stick for 5 days; oral swabs and CPIS scores will be monitored.

06

What researchers measure

Primary outcomes

  1. Changes in Oral Microbial Colonisation

    Oropharyngeal swab samples are collected on Days 1 and 6 to assess the presence or absence of growth of bacterial pathogens associated with ventilator-associated pneumonia and Candida species. Changes in oral microbial colonisation are evaluated by comparing the culture results for each microorganism between Days 1 and 6.

    Time frame: Day 1 and Day 6

  2. Incidence of Ventilator-Associated Pneumonia (VAP)

    The development of ventilator-associated pneumonia (VAP) is determined through clinical assessment by the treating physician, supported by the Clinical Pulmonary Infection Score (CPIS). The CPIS includes six parameters: body temperature, leukocyte count, tracheal secretions, oxygenation (PaO₂/FiO₂), chest radiographic findings, and microbiological culture results. The total score ranges from 0 to 12, with higher scores indicating a greater likelihood of pulmonary infection. VAP incidence is recorded as present or absent.

    Time frame: Day 1 and Day 6

Secondary outcomes

  1. Oral care frequency assessed by the Oral Care Assessment Scale for Intensive Care Patients (OCAS-ICP)

    Oral care frequency and oral health status will be assessed using the Oral Care Assessment Scale for Intensive Care Patients (OCAS-ICP). The scale consists of 10 assessment parameters and 17 factors corresponding to these parameters. Each category is scored from 0 to 4 depending on the presence of relevant factors. The total score obtained from the scale ranges from 0 to 26, with higher scores indicating poorer oral health status and a greater presence of risk factors, and lower scores indicating better oral health status. Patients will be evaluated daily during their intensive care unit stay. Based on the total OCAS-ICP score, oral care will be planned and implemented as follows: patients with a total score of 0-8 points will receive oral care twice daily (2×1), those with 9-17 points will receive oral care four times daily (4×1), and those with 18-26 points will receive oral care six times daily (6×1).Patients will be evaluated daily from Day 1 to Day 6.

    Time frame: Day 1 to Day 5

07

Study locations

1 of 1 sites recruiting
  • Zonguldak Atatürk State Hospital, Ministry of Health, Türkiye
    Zonguldak, 67000, Turkey (Türkiye)
    Recruiting
    • Zonguldak Atatürk State Hospital, Ministry of Health, Türkiye · Contactzonguldakdhs4@saglik.gov.tr · + 90 (0372) 252 19 00
    • Evşen ERTEM, MD/Anesth. · Principal investigator
    • Ayse AYDIN, PhD Can. · Sub investigator
    • Gulten KARAHAN OKUROGLU, Assoc.Prof · Principal investigator
08

References and documents

Publications

  • Diaconu O, Siriopol I, Polosanu LI, Grigoras I. Endotracheal Tube Biofilm and its Impact on the Pathogenesis of Ventilator-Associated Pneumonia. J Crit Care Med (Targu Mures). 2018 Apr 1;4(2):50-55. doi: 10.2478/jccm-2018-0011. eCollection 2018 Apr. PubMed 30581995 ↗
  • Miranda AF, de Paula RM, de Castro Piau CG, Costa PP, Bezerra AC. Oral care practices for patients in Intensive Care Units: A pilot survey. Indian J Crit Care Med. 2016 May;20(5):267-73. doi: 10.4103/0972-5229.182203. PubMed 27275074 ↗
  • Terezakis E, Needleman I, Kumar N, Moles D, Agudo E. The impact of hospitalization on oral health: a systematic review. J Clin Periodontol. 2011 Jul;38(7):628-36. doi: 10.1111/j.1600-051X.2011.01727.x. Epub 2011 Apr 7. PubMed 21470276 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — There is currently no plan to share individual participant data (IPD) with other researchers. This decision takes into account ethical considerations and the importance of protecting patient confidentiality in a critically ill population.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Mar 2027, 17 months after the start.

Of 82 non-industry interventional studies with no phase under Pneumonia, Ventilator-Associated, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 36. This study's planned 17 months is below that.

Counting every sponsor, half of 83 studies reached it within 20 months; a quarter within 10 and three quarters within 36.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Jun 2026 → Mar 2027 and completion Oct 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2025
First posted
Dec 15, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Mar 31, 2027was Jun 2026
CompletionEst.
Mar 31, 2027was Oct 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Nov 9, 2026
Sites
1 site removed. Zonguldak Atatürk State Hospital, Ministry of Health, Türkiye is now Recruiting
Show 1 removed
  • Zonguldak Ataturk State Hospital · Zonguldak, Turkey (Türkiye)
Nov 9, 2026
Primary completion
Jun 30, 2026→Mar 31, 2027
Nov 9, 2026
Study completion
Oct 1, 2026→Mar 31, 2027
Nov 9, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedPatients who have been on invasive mechanical ventilation for less than 24 hours. or less
Exclusion criteria
  • EditedPatients who have been on invasive mechanical ventilation for more than 24 hours before enrollment.
Nov 9, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedIncidence of ventilatorVentilator-associated pneumonia based on the Clinical Pulmonary Infection ScoreAssociated Pneumonia (CPISVAP)Time frame: Day 1 and Day 6
  • ChangedBefore Mean colony-forming unit (CFU) counts of oral bacterial colonizationNow Changes in Oral Microbial ColonisationTime frame: Day 1 and Day 6
Nov 9, 2026
Secondary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameOral care frequency assessed by the Oral Care Assessment Scale for Intensive Care Patients (OCAS-ICP)Day 1 to Day 6 → Day 1 to Day 5
Nov 9, 2026
Contact
Study contact now listed: added a•••@outlook.com · •••9989; added g•••@marmara.edu.tr · •••5701. See the current contact
Nov 9, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Zonguldak Atatürk State Hospital, Ministry of Health, Türkiye · Zonguldak, Turkey (Türkiye)Contact added z•••@saglik.gov.tr · •••1900Contact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Active, not recruiting→Recruiting
    1 site removed. Zonguldak Atatürk State Hospital, Ministry of Health, Türkiye is now Recruiting
    Show 1 removed
    • Zonguldak Ataturk State Hospital · Zonguldak, Turkey (Türkiye)
    Primary completion Jun 30, 2026→Mar 31, 2027
    Study completion Oct 1, 2026→Mar 31, 2027
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedPatients who have been on invasive mechanical ventilation for less than 24 hours. or less
    Exclusion criteria
    • EditedPatients who have been on invasive mechanical ventilation for more than 24 hours before enrollment.
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedIncidence of ventilatorVentilator-associated pneumonia based on the Clinical Pulmonary Infection ScoreAssociated Pneumonia (CPISVAP)Time frame: Day 1 and Day 6
    • ChangedBefore Mean colony-forming unit (CFU) counts of oral bacterial colonizationNow Changes in Oral Microbial ColonisationTime frame: Day 1 and Day 6
    Secondary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameOral care frequency assessed by the Oral Care Assessment Scale for Intensive Care Patients (OCAS-ICP)Day 1 to Day 6 → Day 1 to Day 5
    Contact Study contact now listed: added a•••@outlook.com · •••9989; added g•••@marmara.edu.tr · •••5701. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Zonguldak Atatürk State Hospital, Ministry of Health, Türkiye · Zonguldak, Turkey (Türkiye)Contact added z•••@saglik.gov.tr · •••1900Contact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)
    + 3 other changes: verification date, description and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07283380
Lead sponsor
Marmara University
Responsible party
Sponsor
First posted
Dec 15, 2025
Start date
Oct 1, 2025
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Ayse AYDIN, PhD Cand.
Contact
ayseelaaydin@outlook.com
+ 905314099989
Gulten OKUROĞLU, Assoc.Prof
Contact
gulten.karahan@marmara.edu.tr
+90(0216)7775701
Gulten OKUROĞLU, Assoc.Prof
principal investigator · Marmara University
Ayse AYDIN, PhDCand.
study director · Marmara University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion